44P Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany

The 1L or 2L standard of care (SOC) for patients (pts) with aNSCLC and no targetable genetic alterations [TA] is immunotherapy (IO) with anti-PD-1/L1 agents (PD1/L1) and/or platinum-based chemotherapy (CT). In pts with aNSCLC and EGFR, ALK, or ROS1 alterations, SOC is ≥1 line of tyrosine kinase inhibitors (TKI). The current study aimed to describe RW treatment among pts with PD1/L1 as 1L therapy.